lutadenovec autogene
AXP000161.1 · Cancer vaccine
- Platform
- chimpanzee adenovirus (ChAdV68, non-replicating)
- Originator
- Gritstone bio
- Sponsor
- Gritstone bio
Names
| Name | Type | Source |
|---|---|---|
| lutadenovec autogene | preferred name, INN | curator, ncit |
| GRT-C901 | code | ncit |
| Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901 ambiguous | synonym | ncit |
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- chimpanzee adenovirus C68
- Strain
- ChAdV68
- Replication
- non replicating
- Modifications
- non-replicating great-ape adenovirus vector encoding a patient-specific cassette of up to 20 tumour-specific neoantigens
- Transgenes
- individualised tumour-specific neoantigens
- Route
- intramuscular
- Source
- evidence
Cross-references
- NCI Thesaurus
- C156925
- FDA UNII
- AJ42U9BVW4
Approvals
No regulatory approval recorded.
Clinical trials (3)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05456165 | Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer | Withdrawn | Phase 2 | 2022-05-19 | 2022-09-01 | 0 | Colonic Neoplasms; Colorectal Neoplasms |
| NCT05141721 | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | Active not recruiting | Phase 2/3 | 2022-02-12 | 2027-03 | 700 | Colorectal Neoplasms |
| NCT03639714 | A Study of a Personalized Neoantigen Cancer Vaccine | Completed | Phase 1/2 | 2019-02-13 | 2022-11-10 | 29 | Colorectal Cancer; Gastroesophageal Adenocarcinoma; Non Small Cell Lung Cancer; Urothelial Carcinoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 35970920 | Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. | Nature medicine | 2022 | cited by trial NCT03639714 |
Notes
GRT-C901: individualised neoantigen priming vaccine on a chimpanzee adenovirus vector, the adenoviral half of the GRANITE regimen (prime GRT-C901, boost the self-amplifying mRNA GRT-R902 / sapecmeran autogene, NCIt C156926, which is a separate non-viral program outside this pass). Phase 2/3 in metastatic colorectal cancer; Gritstone filed for bankruptcy protection in 2024. Vector usually described as ChAdV68, derived from chimpanzee adenovirus C68; serotype not verified from a primary source here.
How to cite
lutadenovec autogene (AXP000161.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000161.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.